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Introduction and objectives: Potentially lethal haematological disorders and 
malignancies – such as myelodysplastic syndromes, acute and chronic leukaemias, 
severe aplastic anaemias and lymphomas – represent a heterogeneous group of 
diseases characterised by alterations in the proliferation and function of blood cells. It 
was reported decades ago that patients with acute leukaemia (AL) have signs of specific 
leukaemia-related oral lesions, such as petechias, gingival bleeding, and gingival 
swelling. Previous studies have also concluded that general dental treatment needs to 
be high among haematological cancer patients at the time of diagnosis and before 
cancer treatments, but the data are sparse. Thus, there is a need to gather 
contemporary information on the state of oral health of these patients. 
Poor oral health is considered a risk factor for several diseases, including specific 
cancers, but the associations between oral health and severe haematological 
malignancies and disorders are unclear. The existing knowledge is based on a limited 
number of studies and the results are contradictory. 
Treatments of these disorders and malignancies are often intensive and may include 
chemotherapy, radiation therapy, and haematopoietic stem cell transplantation (HSCT). 
Thus, the elimination of possible oral foci has been suggested in oral health protocols for 
such patients. As well as the disorders and malignancies themselves, their treatments 
are known to affect oral health. As HSCT procedures and success rates have increased, 
a growing number of patients have experienced serious short- and long-term side effects 
and comorbidities. Due to the toxic effects of chemotherapies, total body irradiation, and 
immunosuppression, HSCT recipients are at risk of oral side effects during and after 
HSCT. Side effects of the therapy in the oral cavity are common and approximately 80% 
of patients are affected by comorbidities such as mucositis, hyposalivation, and graft 
versus host disease (GvHD). 
The purpose of this thesis was to investigate the oral health parameters of adult patients 
with severe haematological malignancy or disorder before HSCT and the progression of 
the oral health parameters post-HSCT. The results were compared with controls of 
normal population. Additionally, the associations between oral health parameters and 
hyposalivation with survival were investigated. 
Methods: A group of 572 adult patients referred for dental examination to University 





Basel between 2008 and 2018 was included in the sub-studies of this thesis. From 2008 
to 2016, the data collection was retrospective, and for 2018 prospective. A dental 
examination conducted included the following: decayed, missing, and filled teeth (DMFT) 
index; calculation of number of teeth; stimulated salivary flow rate (SSFR); presence of 
periodontitis; presence of acute infections; panoramic radiographs and if needed, 
additional radiographs. After HSCT, the presence of oral GvHD was additionally 
examined. In the longitudinal part of the study, the patients were examined six, 12, and 
24 months post-HSCT. The changes in SSFR and influence of SSFR on other oral 
health parameters and on six-month survival were examined. 
The control group consisted of 289 adults recruited from the Swiss Bone Marrow Donor 
Registry of the Blood Transfusion Service SRC Basel, Switzerland. Oral examination 
was performed for the controls in University Center for Dental Medicine Basel, in a 
process similar to that previously described – with the exception that radiographs were 
not taken and, instead, a clinical periodontal status was performed. 
In the first sub-study (8.1), the final study population included 143 allogeneic HSCT 
recipients matched with controls by age and sex. In the second sub-study (8.2), a total of 
149 patients who had got their haematological diagnosis not more than six months ago 
were included and compared with a control group of 154 subjects of same mean age. 
For the longitudinal part of the study (8.3), 269 allogeneic HSCT recipients were 
included.  
Results: In the first sub-study (8.1), the mean SSFR and mean DMFT index and number 
of caries lesions were observed to be poorer among HSCT recipients than controls (all p-
values < 0.05). Acute symptomatic infections were observed in nine HSCT recipients 
(6.3%) and none of the controls. The number of teeth was lower among the HSCT 
recipients, but no statistically significant difference was observed. Statistically significant 
differences in the measures of current or previous periodontitis were not observed.  
In the second sub-study (8.2), where patients with newly diagnosed severe 
haematological malignancy or disorder were compared with controls, the mean SSFR of 
the patients was significantly lower than the mean SSFR of the controls (p < 0.005). 
Additionally, the number of caries lesions was significantly higher in the patient group 
than in the control group (p < 0.005). There were fewer teeth and a higher DMFT index in 
the patient group compared to the control group, but the differences were not statistically 
significant. Acute symptomatic infections were observed in eight (5.4%) patients and in 





In the third longitudinal study (8.3), 40 HSCT recipients (14.8%) died within six months 
after HSCT. Among the deceased recipients, hyposalivation and caries were more 
common pre-HSCT than in recipients who survived more than six months (p < 0.05). 
HSCT recipients with hyposalivation pre-HSCT had a higher risk of death (HR: 1.90, 
95% CI: 1.00-3.60; p = 0.044) within six months post-HSCT compared to recipients 
without hyposalivation. Additionally, hyposalivation pre-HSCT was associated with a 
higher DMFT index score (p < 0.05) and a lower number of teeth (p < 0.005) 24 months 
post-HSCT in comparison to those without hyposalivation. 
Conclusions and clinical relevance: Patients with severe haematological disease 
demonstrated a high prevalence of oral disorders at the time of diagnosis and at the time 
of pre-HSCT. Hyposalivation and caries were associated with a lower rate of survival in 
HSCT recipients. In addition, hyposalivation predisposed patients to deterioration of oral 
health post-HSCT. These findings support the recommendations for early dental 
examination at the time of diagnosis. Efficient preventive strategies are important to 
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4 INTRODUCTION – REVIEW OF THE LITERATURE  
In recent years, the associations between oral health and common noncommunicable 
diseases have been studied extensively, with many found to be important [1-3]. 
However, the relationship between oral health and haematological malignancies and 
disorders, as well as the influence of oral health on treatment outcomes for these 
malignancies and disorders, remains contested. This thesis provides more detailed 
evidence on the oral health of patients with severe haematological malignancies and 
disorders. 
Recent scientific reports show that oral health and diseases have an impact on general 
health [1, 2]. Oral diseases and neglect in oral health care can lead to acute and even 
life-threatening general infections, such as septicaemia [3]. Oral diseases are 
widespread, common, and cumulative in nature, and they have been observed to have 
various influences on general health. Oral diseases and many non-communicable 
diseases have same risk factors, but there is also substantial evidence of an association 
between oral health and pathogenesis, for example, in diabetes and cardiovascular 
disease [1, 4]. Recent studies of chronic oral infections, such as periodontitis, have 
shown that this persistent low-grade oral inflammation is associated with several 
malignancies and with overall cancer mortality [5, 6]. To date, there is no conclusive 
evidence that poor oral health is a risk factor for haematological disorders or 
malignancies [6, 7]. 
Several studies have found that the oral health status of patients with haematological 
malignancies prior to cancer treatments may correlate with comorbidities, such as 
mucositis, during and after cancer treatments [8-10]. It has also been suggested that 
cancer treatments can cause oral side-effects via direct toxicity, and that cancer patients 
are more likely to develop oral health problems during and after their treatments [11, 12]. 
The data on the oral health of patients with severe haematological malignancies and 
disorders before and after haematopoietic stem cell transplantation (HSCT) are scarce. 
Moreover, the quality of the data in terms of number of participants, methodologies used, 
and data analyses reported are partially imprecise. Hence, this thesis provides novel 
evidence that offers an insight into oral problems in adult patients with haematological 






4.1 Short introduction to severe haematological malignancies 
and disorders and their treatments 
Severe haematological disorders and malignancies – such as leukaemias, lymphomas, 
and severe anaemias – can frequently affect all blood cell lineages causing neutropenia, 
thrombocytopenia, and anaemia [13-16]. Although the reasons for most haematological 
disorders and malignancies remain unknown, some risk factors have been identified. 
These include exposure to benzene and previous radio-chemotherapeutic cancer 
treatments [13-17]. 
 
4.1.1 Haematological diagnoses 
This subsection details the most common haematological diagnoses relevant to this 
thesis. These diagnoses can be sub-grouped according to many different criteria, such 
as risk level and genotype, but these are not addressed in detail here.  
Myelodysplastic syndrome (MDS) is one of the most common haematological 
malignancies and it consists of a heterogeneous group of diseases characterized by 
dysplasia and cytopenia in myeloid cell lineages. Such patients have an increased risk of 
developing acute myeloid leukaemia (AML). Intensive chemotherapy followed by 
allogeneic HSCT is the only curative treatment. Incidences of MDS are highest among 
older people (> 70 years) [14, 16]. 
AML is the most commonly diagnosed acute leukemic malignancy in adults. AML is 
characterised by proliferation in differentiation of myeloid cell lines (e.g., neutrophils, 
erythrocytes, and platelets). Although AML can occur at any time, the incidence 
increases with age, and it is usually diagnosed among older adults. Chemotherapy 
possibly combined with HSCT is considered as therapy [13, 16]. 
In myeloproliferative neoplasms (MPN), there is an observable increase in the production 
of red or white blood cells, or platelets, produced by bone marrow. Myelofibrosis, 
polycythaemia vera, and essential thrombocytopenia are MPNs. Chronic myeloid 
leukaemias (CML) are also type of MPN, usually diagnosed among older patients 
(average of 60 years). First-line treatment for CML is done with tyrosine kinase inhibitors, 
but if there is primary resistance against tyrosine kinase inhibitors or no response, 





Acute lymphoblastic leukaemia (ALL) affects the lymphoid line of blood cells, causing 
insufficient maturation in lymphocytes (T- and B-cells, natural killer cells). It is more 
common among children than adults. Chemotherapy and, if needed, total body 
irradiation (TBI) are used as first-line treatment. High-risk ALL patients are treated with 
allogeneic HSCT [16]. 
In chronic lymphocytic leukaemia (CLL), non-functioning B-cells accumulate in various 
tissues and organs, such as bone marrow and spleen. It is the most frequent leukaemia 
among adults, and its onset is usually at older age. Its progression is slow. For low-risk 
patients without symptoms, the preferred treatment is regular monitoring of their 
condition. Patients with symptoms and higher risk factor are treated with chemotherapy 
and autologous HSCT, though the only curative treatment is allogeneic HSCT [16]. 
Lymphomas are malignancies affecting the lymphoid system. They are divided into 
Hodgkin’s lymphomas and non-Hodgkin’s lymphomas. Hodgkin’s lymphomas have two 
peaks in prevalence, among young adults (15-35 years) and older adults (> 50 years). 
Hodgkin’s lymphoma is characterised by special Reed-Sternberg giant cells, and the first 
affected areas of this disease are usually the upper body lymph nodes (e.g., neck, 
armpits). Non-Hodgkin’s lymphomas are more common than Hodgkin’s lymphomas and 
several subgroups can be classified. Preferred therapy depends on the aggressiveness 
of the malignancy and the number of sites affected. Chemotherapy, radiotherapy, and 
HSCT are used for treatment [15, 16]. 
Multiple myeloma (MM) is a malignancy affecting plasma cells, the antibody producing 
white blood cells. It can be treated but there is no curative care for the condition. Bone 
lesions are often part of MM; and thus, bone-modifying agents are administered as 
medication to prevent bone fractures. High-dose chemotherapy and autologous HSCT 
are used for eligible patients. Relapse is usual and life-long cancer medications are 
needed [16]. 
Severe aplastic anaemia (SAA) is a disease caused by bone marrow failure. In SAA, 
there is a failure in the production of new blood cells, causing fatigue, elevated risk of 
bleeding, and increased risk of infections. It can occur at any age. The disease is treated 
with allogeneic HSCT, blood transfusions, or immunosuppressive therapy [16]. 
4.1.2 Treatments 
The treatments for severe haematological malignancies and disorders are often 





Chemotherapy is a systemic treatment, in use for more than 100 years. 
Chemotherapeutic agents cause inhibition of cell mitosis and block extracellular 
signalling of cells. Today, multiple different chemotherapeutic agents are used for 
treatments of haematological malignancies. Patients of HSCT often get various 
chemotherapy schemas and multiple cycles, depending on the diagnosis, stage of 
malignancy or disorder, and the condition and age of patient. Typical chemotherapeutic 
agents used for haematological malignancies are anthracyclines, cytosine arabinosides, 
asparaginases, cyclophosphamides, methotrexate, and vincristines [16]. 
The first – and, if needed, second – cycle of chemotherapy is called ‘induction therapy’. 
This aims to eliminate malignant cells and to enable haematological recovery. The 
therapy before HSCT may be myeloablative, meaning complete aplasia: hypo-cellular 
marrow without erythropoiesis, megakaryopoiesis, and myelopoiesis, or given with 
reduced intensity in certain cases where high dose chemotherapy is not tolerated. When 
recovery is achieved, the next cycle of treatment begins – this ‘consolidation therapy’ is 
given to maintain the state of remission. It is important to keep in mind that, during 
aplasia, patients are at high risk for infections. Chemotherapies causing bone marrow 
aplasia are not merely toxic for the haematopoietic system, also mucositis and skin 
toxicity are often reported as side effects [16, 21]. 
 
4.1.3 Haematopoietic stem cell transplantation 
In the 1950s, HSCT was found to be a curative treatment for some end-stage acute 
leukaemia (AL) patients [20]. In recent decades, improved treatment procedures have 
led to a decrease in mortality and morbidity rates, an increase in success rates, and an 
extension of patients’ life expectancy [21, 22]. Nevertheless, a remarkable number of 
patients die after HSCT. The main reasons for death are relapse (30%), graft versus host 
disease (GvHD) (25%) and infection (10%) [23].  
The number of treated patients has increased. In 2017, there were more than 40,000 
HSCT treatments in Europe [24]. Moreover, the use of HSCT is no longer limited to 
severe haematological malignancies and disorders, but it is also used for certain 
autoimmune disorders and solid tumours [25] Therefore, a growing number of patients 
are suffering from short- and long-term comorbidities after treatment. These patients 





The HSCT treatment aims to re‐establish haematopoietic functions, meaning full 
recovery of haematological and immunologic systems, which should result in normal 
physical functioning [20, 21]. Stem cells are collected either from a donor (allogeneic 
HSCT) or from the patient herself (autologous HSCT) [16, 18, 21]. Factors affecting 
HSCT outcome are the patient’s age and stage of diagnosis and, in allogeneic HSCT, 
the histological compatibility of donor and recipient. As the treatment itself might be life-
threatening and several complications are common, the patients should be chosen 
carefully, and a risk-benefit ratio should always be estimated [16, 18, 21]. The main 
indications for HSCT are listed in Table 1. 
Table 1. Main indications for HSCT [25] 
 Autologous HSCT Allogeneic HSCT 















Primary immune deficiency 
Solid neoplasms Neuroblastoma 
Germ cell tumour 
Soft tissue sarcoma 
Ewing sarcoma 
 
Acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), chronic 
lymphocytic leukaemia (CLL), chronic myeloid leukaemia (CML), haematopoietic 
stem cell transplantation (HSCT), myelodysplastic syndrome (MDS), 
myeloproliferative neoplasm (MPN), severe aplastic anaemia (SAA) 
 
The HSCT treatment is given after a conditioning regimen in which different 
chemotherapeutic agents are used to eradicate the recipient’s own haematopoietic stem 
cells, suppressing the immune system before transplantation of haematopoietic 
multipotent stem cells. The patient continues to be aplastic until the transplanted cells 
have cleaved and proliferated [21]. 
In some schemas, haematological cancer patients (HSCT recipients) receive TBI as part 
of their treatment. Irradiation is a well-known, quantity-bound treatment, which can have 





In contrast to autologous HSCT, in allogeneic HSCT, the period of aplasia is longer and 
more severe. Thus, the patients undergoing allogeneic HSCT are at higher risk of 
secondary infections and susceptible to allogeneic transplantation-specific complications, 
such as GvHD. To avoid severe side effects and to enable allogeneic HSCT for older 
people and those with suboptimal conditions, reduced intensity conditioning (RIC) is 
used [21, 25]. The disadvantage of RIC is the greater risk of relapse and reoccurrence of 
the haematological malignancy [25]. 
 
 
The HSCT treatment is followed by engraftment. Engraftment is defined as a stage in 
which neutrophil counts are above 0.5 × 109 /l for a period of three days. Platelet 
engraftment occurs when platelet counts are above 20 × 109/l without previous platelet 
Table 2. Common supportive medications used during and after HSCT 
Medication group Medication Used for 
Immunosupressives Cyclosporine, tacrolimus Required to GvHD 
prevention and treatment 
by calcineurin inhibition 
affecting T-cell proliferation 
 Systemic corticosteroids; 
methylprednisolone and 
prednisone 
Required to GvHD 
prevention and treatment 
by suppression numerous 
immune pathways 
 Mycophenolate mofetil and 
pentostatin 
Required to treatment of 
steroid-refractory GvHD by 
immunosuppression of T-
cell proliferation 




Required for bacterial, viral 
and fungal infection 
prophylaxis 
Bone modifying agents Pamidronate, zoledronate, 
denosumab 
Multiple myeloma patients 
for bone fracture 
prevention 




Gastric ulcer and reflux 
prevention by reduction of 
gastric acid secretion  
Other possible necessary 
medications 









transfusions in the previous five days. Immunological recovery takes usually 3-6 months 
and for some parts even several years to gain full recovery [29]. 
After HSCT, patients usually need a wide range of different medications, some for 
extended periods of time [30-33]. The most commonly provided medications are listed in 
Table 2. It is well known that several medications can reduce salivary flow and that 
polypharmacy increases the risks of hyposalivation, a condition that may lead for further 
oral comorbidities [34, 35] Haematological cancer treatments are known to cause acute 
and long-term oral side effects and, as evidence shows, the side effects of these 
treatments often worsen the patient's quality of life [36-39]. 
 
4.2 Oral health at the time of haematological diagnosis and pre-
HSCT  
4.2.1 Oral leukemic-related manifestations at the time of haematological 
diagnosis 
In the 1960s, Roath et al. and Lynch et al. found that patients with AL had specific AL-
related oral lesions [40, 41]. In later research, depending on the study design and the 
timing of oral examination (in relation to the onset of haematological malignancy or 
disorder), between 4.0% and more than 50% of patients with AL were found to have 
signs of specific leukaemia related oral lesions [42]. The most commonly described oral 
lesions were petechias, gingival bleeding, ulcerations, and gingival hyperplasia and 
swelling. Lynch et al. report that oral lesions are more often found among patients 
diagnosed with advanced disease [41]. As haematological malignancies and disorders 
are today diagnosed in the early stages of the disease, oral signs are seldom the first 
sign leading to diagnosis. However, in a recent study, more than 30% of the patients with 
a new diagnosis of AL had oral mucosal signs related to leukaemia [42]. Differential 
diagnosis of oral manifestations of leukaemia is challenging, and determination of their 
association with haematological malignancies might be difficult. 
4.2.2 Common oral health 
Acute oral mucosal changes are not the only oral diseases or disorders that 
haematological patients have at the time of diagnosis. Recent studies suggest that AL 





time of diagnosis [42, 43]. One study found that more than 40% of 263 AL patients 
needed oral treatment. At the time of diagnosis, they were exhibiting oral symptoms such 
as visible caries, dental pain, and teeth mobility [42]. Another recent study found a high 
prevalence of caries and periodontitis in a group of 39 patients with newly diagnosed AL 
before they received cancer treatments. The study found that the patients had 
significantly more caries and missing teeth than seen in healthy controls [43]. Another 
study reported that, in 24 leukaemia patients, the salivary flow rate was statistically 
significantly lower before the initiation of treatments than among healthy controls [44]. 
Few previous studies have investigated the oral health status of patients pre-HSCT in 
the last two decades. These studies are listed in Table 3. Several of these conclude that 
90% and more of the patients were in need of some dental treatment, and one study 
found that 97.4% of patients had at least one potential dental infection foci [9, 45, 46]. 
Caries prevalence has been observed to vary between 32% [46] and 67% [47]. Different 
degrees of periodontitis have been observed ranging from just 0.6% of patients [48] to 
67% [45]. The prevalence of oral infections was reported to be 6.4% in a study of 
autologous HSCT recipients and patients receiving high-dose chemotherapy [49]. 
According to the study results, the need for oral or dental treatment varies depending on 
the study setting and the descriptives of the patients. The treatments given by dental 
professionals were often oral hygiene information, scaling, filling, or extractions [9, 45, 
47, 50-52].  
At the time of HSCT, some patients had already received treatments for their underlying 
disease, with some having been treated for several years. These previous therapies 
could have affected their oral health, particularly their salivary flow rate, if 
chemotherapies and TBI had been used. Studies on the effect of chemotherapies on 
salivary flow rate in HSCT recipients are inconsistent and sparse [39]. These effects, 
together with the stressful period of undergoing treatments causing fatigue, could have 
led to deterioration of oral health pre-HSCT [53]. However, as described previously, 
patients with newly diagnosed AL had worse oral health parameters than healthy control 













4.3 Oral health during and after HSCT 
Oral side effects occur frequently during intensive treatments of haematological 
malignancies and disorders. A study of 79 haematological patients revealed that almost 
half had some therapy-related oral comorbidities [54]. Evidence also suggests that 
patients’ previous oral health problems, such as periodontitis, can also have an impact 
on the severity of other treatment related side effects, including mucositis [10, 47]. 
 
4.3.1 Oral infection foci  
The oral source as foci of systemic infection was recognised in the 19th century research 
[55]. Contemporary understanding holds that there are different ways in which oral 
diseases act as source of systemic infection [3]. Acute infections, which spread from oral 
and dental tissues (e.g., decayed teeth causing abscesses and even septicaemia) are 
well understood [3, 55]. In recent decades, it has been observed that persistent low-
grade inflammation, such as chronic gingivitis or periodontitis, may increase the 
likelihood of developing systemic disorders and that these oral inflammations are 
associated with increased cancer incidences and cancer mortality [2, 5, 6, 56, 57]. Low-
grade inflammation is defined as chronic production of inflammatory factors, such as 
slightly increased inflammation marker C-reactive protein [58]. 
Researchers have assumed that during neutropenia and immunosuppression, oral 
microbes can cause both acute local odontogenous and systemic infections among 
patients undergoing high-dose chemotherapies and HSCT [59, 60]. However, the results 
of previous studies among HSCT patients about potential oral foci causing infections 
during and after chemotherapies and HSCT are inconsistent. It has been estimated that 
oral screenings and treatments conducted on patients before HSCT would reduce 
systemic infections by a third. Pre-HSCT elimination of obvious dental foci could 
theoretically prevent one in 500 deaths [61]. Additionally, oral screening and dental foci 
elimination would also reduce overall medical care costs by preventing cases of post-
HSCT comorbidity, such as bacteraemia [52]. 
Various acute and chronic oral diseases and disorders have been listed as possible oral 





gingivitis and periodontitis, root canal infection and periapical periodontitis, impacted 
teeth with pericoronitis, and mucosal ulcerative lesions [21, 45, 62-65]. 
In the 1980s and up to the beginning of the 1990s, several studies suggested that oral 
infections can cause fever and that dental foci can act as a source of systemic infections 
in patients undergoing HSCT [60, 66-69]. Recent studies have not fully confirmed this, 
although some cases have been observed. One study compared patients who received 
complete, invasive dental treatment before chemotherapy with patients who had no 
dental treatment. A significant difference was observed between the groups. Patients 
with complete, invasive dental protocol had significantly fewer oral and systemic 
infectious complications [65]. In addition, in a study of 18 allogeneic HSCT patients, 
those who had gingivitis or periodontitis had higher risk for bacteraemia, compared with 
patients without periodontal disease [70]. In contrast, another recent study compared 
patients whose dental treatment needs had been compromised with patients whose 
dental treatment needs had been fulfilled and found no difference in bacteraemia risk 
during and after HSCT [71]. 
Due to time limitations and poor overall health condition of haematological patients, 
dental practitioners cannot always conduct recommended procedures to eliminate oral 
infections [50, 51, 71]. In healthy individuals, wound healing after tooth extraction takes 
approximately two weeks. In haematologically compromised patients, wound healing 
may be prolonged and/or substantially impaired. Risk of complications, such as bleeding 
and secondary infections, is evident; and such complications can postpone the cancer 
treatments [50, 59]. Dental procedures themselves often cause bacteraemia, for which 
proper antimicrobial prophylaxis is needed. Furthermore, invasive dental procedures are 
not the only factors, daily routines and basic oral care – such as tooth brushing and, in 
people with periodontitis, even chewing – are likely to cause bacteraemia [72-74]. 
However, advanced periodontal disease diagnosed by radiographs was not identified as 
a risk factor for septicaemia or mortality in 77 HSCT recipients. Septicaemia-associated 
blood cultures were found in 64% of the patients, but no association between bone loss 
and periodontal or oral origin blood cultures was observed [75]. Furthermore, in a study 
of 58 allogeneic HSCT recipients, no significant correlations were found between dental 
foci and systemic infections, mucositis, and survival rate post-HSCT [76]. A preliminary 
study of 38 patients who received intensive chemotherapy (and minimal pre-treatment 
dental procedures) concluded that chronic oral foci could be left untreated. This was 
because, during chemotherapy, dental problems did not usually progress to an acute 





common among patients with higher frequency of oral disorders, though the difference 
was not statistically significant [9]. In a study of patients receiving intensive 
chemotherapy or autologous HSCT, it was found that chronic asymptomatic oral foci do 
not appear to create additional risks during cancer therapies [49]. Similarly, a study of 
166 HSCT recipients compared patients who received limited and intensive dental care, 
respectively, and found no difference in septicaemia incidences [10]. A recent study 
found no association between oral foci and survival or severe infection complications 
within six months post-HSCT [77]. As contemporary treatment protocols recommend, all 
patients receive antimicrobial prophylaxis during and after HSCT for infection 
prophylaxis. As expected, the use of antibiotics also prevents infections of oral origin. 
Thus, the common practice of administering antibiotics can lead to study biases, as 
prophylactic anti-infective medication also prevents oral infections. If this study bias is 
not taken into account, it can lead to underestimation of the risk of oral origin foci and 
systemic infection. 
 
4.3.2 Fungal infections 
After HSCT, patients are at high risk of developing secondary infections. Invasive and 
systemic fungal infections are a considerable cause of morbidity and even mortality [32, 
33]. Patients are also susceptible to oral local candida infections. Although candida 
species are considered commensals of the normal oral flora and their relative proportion 
is limited in healthy individuals, they can act as an opportunistic pathogen, when 
provided with sustainable environmental condition and nutrients from the host [78]. 
Changes in oral microbiome may occur in patients who receive prophylactic antibiotics 
and immunosuppression after HSCT. Thus, after HSCT, candida species can gain pre-
dominance and cause infection [32, 78]. Patients also often have reduced salivary flow 
rates during and after HSCT. This, along with the possible reduction of oral hygiene, can 
act as risk factors for candida infection [67, 78-80]. In patients treated with topical 
corticosteroids for oral chronic GVHD post-HSCT, the risk of oral candidiasis further 
increases [78]. In a review of patients receiving cancer therapy, the oral colonisation of 
fungal species during and after chemotherapy treatments was over 70%, and oral 
candidiasis was observed in 38% of cases. Today, the post-HSCT routine involves the 
provision of prophylactic anti-fungal medication to patients to avoid fungal infections and 





Oral candidiasis can have various symptoms, or it can be asymptomatic. 
Pseudomembranous and erythematous candidiasis are the most frequently observed 
forms associated with cancer treatments. Superficial whitish pseudo-membranes can be 
detected in the labial and buccal mucosa, on hard and soft palate, and on the tongue. 
The white surface membrane can be removed easily by gentle rubbing. Underneath the 
whitish membrane, the mucosa is erythematous. Patients report experiencing burning 
sensation and taste disturbances. Loss of filiform papillae can also be observed. 
Systemic antifungal medications, which are administered to the patients, prevent oral 
manifestations of candida [32, 78]. 
Good oral hygiene should be maintained for effective prevention of oral candidiasis. 
Special care should be taken of patients with dentures. The denture should be 
decontaminated with the same anti-microbial agent as the oral cavity to prevent re-
contamination by the microbial flora [63]. 
 
4.3.3 Viral infections 
It is understood that HSCT recipients are at high risk of viral infection during the 
neutropenic phases, because antiviral lymphocyte functions are reduced. The viral 
infection can be exogenous, most often respiratory viruses or an endogenous re-
activation of a herpes virus, adenovirus, or hepatitis. The most common oral viral 
infections are re-activated forms of the herpes simplex virus (HSV) HSV-1 and HSV-2, as 
the majority of adult population are latent carriers of the virus. Symptoms include pain in 
the mouth, which is most severe in the beginning of infection, followed by burning and 
itching sensations. Oral vesicles occur on buccal mucosal membranes and often also 
extra orally on the lips. These lesions usually suggest a re-activation of a virus, whereas 
intraoral lesions combined with systemic symptoms are an indication of a primary 
infection. The vesicles develop into ulcers. Lesions are typically completely healed within 
8-10 days [81]. The HSV infections were found to be more frequent among cancer 
patients if oral ulcerations, caused for example by mucositis, were present compared to 
in patients without oral ulcerations [82]. 
An anti-viral prophylactic medication (e.g., valacyclovir or aciclovir) is routinely provided 
to HSCT patients to prevent oral herpetic infections [83]. Varicella zoster is another 
member of the HSV family often re-activated among HSCT recipients [84]. If the re-
activation of the virus occurs in the facial area, this can affect the trigeminal nerve and 





allogeneic HSCT recipients found that positive DNA samples of Epstein Barr virus were 
a significant predictor of ulceration of keratinized mucosa [86]. 
 
4.4 Mucositis 
Oral mucositis is a toxic reaction to chemotherapies and irradiation to the mucosa. The 
whole alimentary tract can be affected, causing severe pain and dysfunction resulting in 
diarrhoea. Due to the loss of mucosal barrier functions, severe, even lethal effects can 
occur. The scope of this thesis is oral health, thus oral mucositis is addressed here in 
more depth. 
Oral mucositis occurs in 75-100% of patients who receive high-dose conditioning 
chemotherapy before HSCT. It occurs to a lesser extent when conventional 
chemotherapy is used [27, 87]. Depending on the grade of oral mucositis, it can cause 
erythema, mild to severe pain, and ulcerations, which might act as sites for secondary 
infection and cause nutritional impairment [27]. In a study of HSCT patients, 42% 
reported oral mucositis, more precisely mouth soreness, as the most debilitating 
comorbidity caused by the treatments [88]. Oral mucositis in patients undergoing HSCT 
is linked with worse clinical outcomes. Patients with severe oral mucositis stayed in 
hospital for prolonged periods, compared to patients without mucositis or mild mucositis 
[89, 90]. 
Mucositis has different grading systems. In most, the measured elements are symptoms, 
clinical signs of the disease and the impact that mucositis has on general functioning of 
the patient. Widely used grading scales for clinical and research purposes are provided 
by the World Health Organization (WHO) and the National Cancer Institute (NCI) – the 
common toxicity criteria (CTC) [91, 92]. According to WHO, the grading scale begins at 
grade 0 (no signs) and ends with grade 4 (alimentation not possible). The grade 1 
category includes erythema or soreness. Grade 2 includes erythema and ulcerations but 
with an ability to eat solid foods. Grade 3 classification indicates ulcers and a 
requirement for a liquid diet. The classification system issued by NCI-CTC starts from 
grade 1, mucositis with asymptomatic or mild symptoms, and continues to grade 4 
mucositis, which has life-threatening consequences for which urgent interventions are 





Several procedures are recommended for prevention and reduction of mucositis 
symptoms. Recommendations for prevention and treatment of oral mucositis include 
cryotherapy (placing ice in the mouth during chemotherapy delivery), low-level laser 
therapy, good oral hygiene, rinsing mucosal membranes with saline or sodium 
bicarbonate mouthwash, and pain medications when needed [27]. In a recent preliminary 
study, it was reported that treatment with hyperbaric oxygen could reduce the prevalence 
of mucositis [93].  
Poor oral health of patients before therapy is associated with mucositis and severe 
intraoral pathology during neutropenic phases [10, 47, 94]. Patients with periodontitis 
and gingivitis had statistically higher rates of mucositis, when compared to those without 
periodontal diseases [9, 94]. The presence of periodontitis-related bacteria, such as 
Porhyromonas gingivalis, was associated with ulcerative mucositis [8]. Evidence 
suggests that professional dental cleaning and scaling pre-HSCT could reduce the 
prevalence and grade of mucositis [95]. It is also advisable that patients receive 
information about the importance of oral hygiene during the therapies, as this may 
reduce the severity and duration of oral mucositis [10, 27, 94-96]. 
Chlorhexidine rinsing is often provided to reduce the bacterial load during neutropenia, 
especially if oral hygiene cannot be maintained at an optimal stage. As chlorhexidine can 
be toxic to mucous membranes, its use to prevent mucositis is not recommended and 
should be avoided if mucositis appears [27, 63]. Use of chlorhexidine can also lead to 
minor reversible comorbidities, such as taste disturbances and colouring of teeth and 
mucosal surfaces. 
 
4.5 Salivary flow rate changes during and after therapy and their 
consequences 
Saliva has many important roles in the oral cavity (Table 4). It is a protective lubricant, 
which maintains a healthy environment for hard and soft tissues of the oral cavity; it has 
a dominant role in enamel and dentin remineralisation; it regulates the oral microbiome; 
and it is essential for the ability to speak, sleep, and eat comfortably [35, 97-99]. In case 
of hyposalivation, the cleaning, remineralisation, and protective effects of saliva are 
affected due to a lack and changes in the composition of saliva. One evident and well-
known risk of prolonged hyposalivation is an elevated risk of caries [97]. The functions 





Hyposalivation (e.g., insufficient salivary flow) is defined in most of the guidelines as 
0.7ml/min or under that of stimulated salivary flow rate (SSFR) and 0.1ml/min or under 
when unstimulated [34]. Hyposalivation can lead to acute and long-term comorbidities 
such as caries, periodontitis, and oral candidasis [34, 35]. On the other hand, xerostomia 
(a subjective sensation of oral dryness) is a symptom which is not dependent on salivary 
flow rates, but is instead probably due to changes in the consistence and quantity of the 
saliva [35]. Xerostomia may appear even when the salivary flow rate stays above the 
diagnostic limit for hyposalivation [34]. 
 
Salivary flow rate decreases due to cytotoxic effects of chemotherapies and HSCT on 
salivary glands [100-102]. However, the reasons for and mechanisms of hyposalivation 
caused by chemotherapy are still not fully understood. It seems that some patients may 
temporarily suffer from hyposalivation during and following cancer chemotherapy, while 
others do not. It is likely that there are several different mechanisms that determine how 
different regiments and HSCT affect salivary glands [39]. An even greater decrease in 
salivary flow rates has been observed in cases where patients received TBI [103]. It is 
assumed that this is associated with the direct toxicity of irradiation and its effect on 
salivary glands. However, HSCT-related reduction in salivary flow rate is mostly 
reversible, although it can take anything from several months to a year before normal 
rates of salivary flow is observed in recuperating patients [102, 103]. A study of 228 
allogeneic HSCT recipients revealed that hyposalivation (SSFR ≤ 0.7ml/min) can often 
be detected before HSCT, with 40% of patients suffering from it. Six months after 
treatment, 51% of recovering HSCT patients had hyposalivation, and 31% a year later. 
Table 4. Functions and components of saliva 
Function Components Effect 
Lubrication Total fluidity and salivary 
flow rate 
Enables swallowing and 
speaking  
Buffer capacity Bicarbonate, Phosphate Neutralisation of acids 




Protective coating Mucins Formation of protective 
pellicle on tooth surface 
Antibacterial activity Lysozyme, Lactoferrin, 
Lactoperoxidase, Secretory 
Immunoglobulin A 
Bacteria cell wall 
degradation, inhibition of 
biofilm formation, microbial 
agglutination 
Digestive functions Amylase enzyme, 
Proteases 






There was a continuing improvement, as two years after HSCT only 21% of patients 
suffered from hyposalivation [103]. However, some patients recovering from HSCT had 
reduced salivary flow rates and xerostomia years after completing their HSCT treatment 
[37, 103, 104]. Thus, hyposalivation is often, but not always, reversible. It is also noted 
that, in a small study of 24 leukemic patients, the salivary flow rates were statistically 
significantly lower before the initiation of any cancer treatments than among the healthy 
controls [44]. 
As well as the amount of saliva, its composition can also change during cancer 
therapies. Salivary changes can occur immediately after HSCT [102]. There is the 
possibility of an inflammatory response in which levels of secretory immunoglobulin A 
are decreased and levels of proinflammatory cytokines and salivary albumin are 
increased. Some studies discovered measurable changes in saliva composition of HSCT 
recipients half a year after treatment. The antimicrobial defence mechanisms of saliva 
had changed due to an increase in the levels of secretory protease inhibitors and 
lactoferrin [102, 105]. There is also evidence that the buffer capacity of saliva decreases 
after chemotherapy and HSCT, leading to a shift to more virulent and cariogenic 
composition of microbiome composition in the oral cavity [100, 106, 107]. 
Hyposalivation and xerostomia have been identified as the most important contributors to 
the worsening of the quality of life after cancer therapies [37, 38, 108]. The effects of dry 
mouth include impaired taste, sleeping problems, and speaking difficulties – dysfunctions 
which affect both physical and mental wellbeing of the patient [35, 36, 97]. Another 
unwanted side effect that can impair the patient’s quality of life is the direct toxicity of 
chemotherapies and irradiation of oral mucosal membranes. Radiation can harm taste 
and olfactory receptors and cause taste disturbances. Chemotherapy-related taste 
disturbances, including bitter taste sensations, are usually short-term and reversible, but 
changes that have lasted for months and even years have been reported [36, 104, 109]. 
When treating patients who experience dry mouth and hyposalivation, the main goal is to 
ease their symptoms and prevent comorbidities. The patient should be advised about the 
importance of adequate hydration and recommended to take small sips of water as often 
as needed. Most available moisturising agents provide only short-term relief to dry 
mouth, but they can be administered if patients gain temporary relief when using them. 
Sugar-free candies and chewing gums can also be used to stimulate salivary flow. To 
prevent caries, topical fluorides (rinses, toothpaste, gels) should be used as part of daily 





restricted to minimise acid attacks and demineralisation of teeth. However, adequate 
calorie intake should be ensured and patients’ overall situation taken into account [35]. 
4.6 Common chronic oral infections after HSCT 
There is insufficient knowledge of the chronic oral infections, periodontitis and caries, 
with which HSCT recipients commonly suffer. Only a small number of studies with short 
follow-up times have investigated the prevalence and incidence rates of periodontitis, 
and the number of decayed, missing, and filled teeth (DMFT index) on patients 
recuperating from HSCT treatment [46, 94, 110, 111]. In most cases, chronic oral 
infections progress slowly. Oral microbiome composition and level of oral hygiene has a 
remarkable impact on their development [34, 35, 99]. 
In a study of 36 HSCT recipients, the patients were examined first before HSCT 
treatments and a second time six months after their treatment. A statistically significant 
increase was seen in the DMFT index scores [46]. A questionnaire-based study 
conducted with patients who had received HSCT between one and more than 10 years 
ago found that self-reported incidences of oral comorbidities were high. Caries was 
reported by 36.7% of the study participants and gum disease only by 16% [110]. 
Improvements in periodontal health three and six months after HSCT were reported in 
two studies of 36 and 29 patients, respectively, who had followed an intense oral care 
programme and received anti-infective treatment pre-HSCT. There was a notable 
reduction in gingival inflammation [94, 111]. 
 
4.7 Long-term oral comorbidities after chemotherapies and HSCT 
4.7.1 Graft versus host disease (GvHD) 
GvHD is a complication caused by allogeneic HSCT. GvHD is a complex alloimmune 
inflammatory reaction in which donor B- and T-cells, in conjunction with certain other 
donor cells, become activated, causing damage to host tissues and becoming a 
significant cause of morbidity and mortality after HSCT [112-114]. The disease is divided 
in two types: acute GvHD (aGvHD) and chronic GvHD (cGvHD) [115, 116]. 
Acute GvHD affects the skin, gastrointestinal tract, and liver and can cause numerous 





[114, 116, 117]. It typically appears shortly (within 100 days) after HSCT, but later 
manifestation is possible. 
In contrast to aGvHD, cGvHD usually occurs later and the symptoms are different. While 
cGvHD can be an extension of aGvHD, it can also occur without previous signs [115, 
117]. The organs affected by cGvHD are mouth, eyes, skin, genitalia, oesophagus, lungs 
and muscles and fascia, and the condition can be restricted to one organ or be 
widespread [116]. Chronic GvHD occurs in approximately 40-70% of allogeneic HSCT 
recipients, and incidences have been increasing in recent decades [112, 118-120]. 
The diagnostic criteria for oral cGvHD, according to the National Institutes of Health 
(NIH), includes the typical lichenoid changes of oral mucosa, which occur most often in 
the buccal mucosa and on the tongue, though other intraoral surfaces and the lips may 
be affected. Ulcerations and erythema can be associated with the disease, but these are 
not considered diagnostic signs by themselves, nor are isolated hyperkeratotic 
leukoplakic plaques [121]. Typical symptoms associated with oral cGvHD are xerostomia 
and hyposalivation [101, 120]. Decreased range of motion in the jaw can be a sign of 
diffuse sclerosis of submucosa. In GvHD diagnosis, a scale of 0-3 (ranging from no 
involvement to severe impairment) is used for each organ. Clinical diagnosis using NIH 
guidelines might be challenging and other additional symptoms should be recorded [116, 
122]. Furthermore, other undefined and clinically cGvHD-related manifestations or 
atypical signs and symptoms may appear [116, 121]. 
There is evidence that cGvHD can cause late changes in salivary flow rates and 
confound saliva functions [101, 123-125]. Although it has been suggested that 
hyposalivation is associated with cGvHD, not all studies confirm the correlation between 
mucosal changes and reduced salivary flow rates [102]. One study concludes that 
although severe cGvHD is associated with oral dryness [37], while another [126]  
demonstrated no significant changes in salivary flow rates at onset of cGvHD. Therefore, 
it has been proposed that changes in salivary gland functions may be a separate 
manifestation of cGvHD that differs from mucosal cGvHD findings [122, 125]. 
Few studies and case reports describe patients with oral cGvHD who develop rampant 
caries. Factors predisposing patients to cGvHD-related caries are reduced salivary flow 
rate, modified composition of saliva, changes in the oral microbiome, restricted ability to 
open one's mouth, and pain in the mouth (with the latter two potentially leading to 
reduced oral hygiene). Patients experiencing these symptoms are at high risk of 





rapid, several teeth are seriously affected, and occurrences of cervical and root caries 
are typically observed [124, 127, 128]. Carious teeth are prone to fractures and the sharp 
edges of fractured teeth may cause irritation on mucosal surfaces, thus provoking the 
appearance of mucosal lesions [127]. 
Local therapy aims to relieve symptoms in the oral cavity and maintain mucosal integrity. 
It is primarily used if oral cGvHD is resistant to systemic treatment or when the oral cavity 
is the only site affected. Commonly used medications are steroids, such as budesonide 
and dexamethasone, and calcineurin inhibitor tacrolimus [129, 130]. The knowledge and 
effectiveness of the local therapy remains limited [130]. Maintaining good oral hygiene is 
important for preventing secondary infections, including local dental infections, such as 
periodontitis and caries [112]. The general recommendation is that patients are 
frequently invited to oral examinations, as this will help to detect possible early signs of 
cGvHD-related oral comorbidities. 
 
4.7.2 Other long-term comorbidities 
Guidelines for oral care regarding HSCT patients mention that orofacial pain, especially 
tooth sensitivity, is a possible comorbidity that may occur after HSCT [63]. Orofacial pain 
is described as pain with a musculoskeletal, sinogenic, neural, or dental origin in the 
frontal part of the head, including the oral cavity [131]. There are no specific studies with 
HSCT patients on the prevalence and grade of tooth sensitivity during and immediately 
after HSCT. A questionnaire-based study with a group of 48 patients five years after 
HSCT and a healthy control group found no difference in tooth sensitivity between the 
groups [104]. The assumption of higher risk for tooth sensitivity is likely to be based on 
clinical implications or extrapolations from studies of head and neck cancer patients. 
However, several studies have been conducted among patients with head and neck 
cancer, and a third of these continued to experience orofacial pain, including tooth 
sensitivity, six months after completing cancer therapies. It must be noted that the 
invasive treatments and high-dose local irradiation treatment of solid tumours differ 
strongly from HSCT treatment procedures [132]. In addition, neurotoxicity, which can 
cause orofacial pain, most often jaw pain, is a side effect of chemotherapies and is 
suffered by other cancer patients [12, 28, 133]. Reversible pulpitis-like pain caused by 
neurotoxicity of high-dose chemotherapy to the mandibular nerve has also been 
observed [11]. However, no studies have specifically shown the relationship between 





In previous studies of HSCT recipients, a high risk of solid secondary malignant 
neoplasms, including oral squamous cell carcinoma, has been observed. The risk for 
secondary cancer development increases with time. Follow-up examinations five years 
after HSCT revealed that the risk of secondary malignancy development had increased 
from 1.2% to 1.6%; and 15 years after treatment, the risk had increased from 3.8% to 
14.9%. It has been observed that the risk of secondary malignancy development was 
higher if TBI was applied [135]. Another study concluded that that the risk of secondary 
oral cancer was more than 10 times higher after HSCT than in the normal population 
[136].  
In MM patients, bone-modifying agents, such as bisphosphonates and human 
monoclonal antibodies (denosumab), are frequently used for medication. A severe side 
effect of these medications is osteonecrosis of the jaw [31]. Medication-related 
osteonecrosis of the jaw is a potentially serious intra oral or extra oral bone fistula, with 
exposed bone. Medication-related osteonecrosis is diagnosed in patients without 
previous radiation to the jaw region and if fistula does not heal within eight weeks. It may 
occur in the maxilla or the mandible, but mandible is more often affected. Medication-
related osteonecrosis has been diagnosed in between 1% and 9% of the patients using 
bone-modifying agents for their advanced cancer. To reduce the risk of osteonecrosis, 
preventive oral care assessment should be provided prior to medication 
(bisphosphonates, denosumab). Knowledge about prevention and treatment of medical-
related osteonecrosis remains limited [137]. 
 
4.8 Contemporary oral health protocols pre-HSCT 
Several guidelines and protocols have been published about the oral healthcare of 
HSCT patients [21, 27, 45, 61-65, 138]. The existing protocols for managing oral 
diseases and associated infectious complications in HSCT recipients are commonly 
based on extrapolations from a few clinical studies and on clinical experiences of other 
oncological diseases, such as head and neck cancer and other solid organ 
transplantations [139]. Dental therapy provided before chemotherapies and HSCT varies 
between different institutions worldwide, from minimal invasive care to radical dental 
treatment [63, 140]. However, according to previous studies, not all HSCT recipients are 





healthcare centres, or they might be skipped due to time limitations owing to the urgent 
need for cancer treatments and weakened overall health condition [51, 62, 141]. 
 
In general, oral care guidelines recommend that a clinical oral examination is conducted 
and radiographs taken if needed. Acute infections should be eliminated. The oral 
examination should be done as early as possible to provide the necessary dental and 
oral treatments before commencing the HSCT therapy [62]. 
A series of guidelines are published by the Multinational Association of Supportive Care 
in Cancer (MASCC), the International Society of Oral Oncology (ISOO), and the 
American Society of Clinical Oncology (ASCO) for clinicians to help with pre- and post-
cancer treatments, preventive interventions, and supportive care. They include a position 
paper on basic oral care for HSCT patients, reviews about oral care management of 
mucositis, reviews of studies made on medications and other supplements used for 
mucositis treatments, and a clinical guideline for medication-related osteonecrosis of the 
jaw [27, 63, 137, 138]. 
The most radical guidelines for oral healthcare recommend that all possible foci be 
eliminated before cancer treatments. This is similar to the oral treatment guidelines for 
head and neck cancer patients, who receive local irradiation of the oral area [63]. Some 
treatment protocols advise that oral treatments should be tailored to individual needs, 
according to the toxicity of given regimen and the risk level of oral and infectious 
complications [62]. The cancer treatment may need to be started as soon as possible. 
Thus, lack of time, low thrombocyte counts, severe neutropenia, and general health-
related issues are factors that can prohibit invasive oral treatment prior to cancer 
treatment. Oral function should be maintained whenever possible, especially when tooth 
extractions are considered. The ability of the patient to eat comfortably with the 
remaining teeth and dentures after HSCT should be a concern [63]. Sharp and fractured 
teeth should be removed, and ill-fitting dentures and orthodontic appliances avoided, as 
this can prevent mucosal irritation and reduce the risk of bleeding and infection during 
HSCT [62]. 
Almost all oral care protocols suggest maintaining proper and intensive oral hygiene 
before, during, and after HSCT, including rinsing frequently with bland solutions such as 
saline, disinfection of dentures, use of soft toothbrushes, and use of toothpaste with 
fluoride. Patients should also be informed before HSCT about possible comorbidities, for 





Regular oral examinations are recommended after completing HSCT. This ensures that 
late comorbidities (e.g., caries) are treated accordingly and preventive measures are 
taken as early as possible. In the case of reduced salivary flow rates, additional use of 
fluoride supplements is recommended. Where there is limited mouth opening ability due 







5 AIMS OF THE STUDY  
As the number of HSCT procedures and their success rates have increased, a growing 
number of patients have experienced short- and long-term side effects and 
comorbidities. There is thus a need for a better understanding of the general prognosis 
of HSCT-related oral side effects and how they affect patients’ oral status and well-being. 
However, recent knowledge of the oral health of HSCT patients at the time of diagnosis 
and pre-HSCT, compared to that of the normal population, remains sparse. 
This thesis aims to investigate the oral health of adult patients who are newly diagnosed 
(<6 months) with severe haematological malignancy or disorders, and patients who are 
receiving HSCT treatment, both pre- and post-HSCT. In particular, the research 
examines the prevalence and aetiology of oral diseases and disorders and the dental 
treatment needs of patients with severe haematological malignancy or disorders, 
compared with controls of the normal population. Additionally, the progression of oral 
diseases and disorders and their associations with overall treatment outcome and oral 
comorbidity are examined regularly for up to two years. 
 
5.1 Specific objectives  
The first sub-study (8.1) describes the oral health of adult HSCT recipients (pre-HSCT), 
compared with an age- and sex-matched control group. The oral health parameters 
assessed include radiological attachment loss (RAL) indicating periodontal health status, 
caries prevalence, number of teeth, prevalence of acute infections, SSFR and DMFT 
index. 
The second sub-study (8.2) considers the state of oral health of adult patients with 
severe haematological malignancy or disease, whose diagnosis was not older than six 
months. These patients were compared with age-matched controls. An additional aim of 
the study was to compare oral health parameters within the patient group according to 
different diagnoses and treatment-related factors, including medications and 
chemotherapies. 
The third sub-study (8.3) evaluated changes in the abovementioned oral health 
parameters pre-HSCT, compared with oral health status at 6, 12, and 24 months post-





HSCT was analysed. The SSFR was collected at every appointment and changes were 
assessed over the observation period of 24 months. The association of pre-HSCT SSFR 
with GvHD post-HSCT was analysed. Finally, the study aimed to determine whether 






6 HYPOTHESES  
Based on previous studies and clinical observations, the following hypotheses are 
proposed: 
•  At the time of diagnosis and pre-HSCT, patients have an enhanced need for 
dental treatment. 
• At the time of diagnosis and pre-HSCT, patients have worse oral health than 
control subjects without severe haematological malignancy or disorders. 
• Post-HSCT, patients are at a very high risk of oral infection, particularly caries. 
• Poor oral health parameters can predispose patients to mortality after HSCT. 
• Salivary measurement of patients pre-HSCT is a potential predictive tool for 







7 PATIENTS AND METHODS 
7.1 Ethical declaration 
This research project was conducted in line with the World Medical Association 
Declaration of Helsinki principles of good clinical practice and local legally applicable 
requirements. 
The studies were approved by the Ethics Committee Basel (EKBB) Ethikkommission 
Nordwest- und Zentralschweiz (EKNZ), Switzerland. This includes both the retrospective 
part of this study (Ref.Nr. EK: 311/10) and the prospective part (EKNZ:2017-02268), as 
well as the control group study (Ref.Nr. EK:357/08) and the use of haematological data 
from the medical records (Ref.Nr. EK:117/05). 
 
7.2 Patients 
The study was carried out in the University Center for Dental Medicine Basel (UZB) 
Department of Oral Health & Medicine (OHM) in collaboration with the Department of 
Haematology, University Hospital of Basel, Switzerland. Approximately 100 patients 
undergoing annual HSCT in the University Hospital Basel were examined in the UZB for 
their oral health. Included in the study were all adult (> 18 years) HSCT recipients who 
received an oral examination. 
This thesis comprises three observational studies – starting retrospectively with patients 
who received HSCT and got oral examination pre-HSCT in UZB between 2008 and 2016 
(n = 475). For 2018 onwards, the study design was prospective (n = 97). 
 
7.3 Study design and measurements 
All subjects included in the retrospective part of this study have undergone thorough oral 
examinations by an experienced dentist pre-HSCT and at 3, 6, 12, 24, 60 months post-
HSCT in the Department of Oral Health & Medicine, UZB (former School of Dental 





Basel). For the prospective part, oral examinations were conducted similarly by the 
author of the thesis in Department of Oral Health & Medicine.  
All the clinical parameters of oral health needed for this study (including DMFT index 
score, salivary flow measurements, caries incidence, number of teeth, presence of acute 
or chronic oral foci, and presence of oral GvHD) were collected during these clinical 
examinations.  
A panoramic dental x-ray was taken from all pre-HSCT patients. In addition, intraoral x-
rays were taken when required and x-rays of the patients were re-examined by a 
radiologist when necessary. Chronic infectious dental foci were noted. The findings 
included apical periodontitis in the x-rays, RAL > 3mm, non-vital teeth with deep caries, 
root remnants, and partially erupted wisdom teeth with chronic pericoronitis. Acute oral 
infections were diagnosed when fistulas, symptomatic periapical processes, symptomatic 
deep caries, acute pericoronitis, wounds/ulcers, or acute periodontal abscesses were 
observed. 
The SSFR of the patients was measured at every appointment. Stimulation was 
achieved by asking the patient to chew a neutral paraffin gum continuously for six 
minutes. After one minute, the patient's whole saliva secreted over five minutes was 
collected and converted to mL/min. Measurements under 0.7mL/min were considered 
hyposalivation [97]. 
Relevant data from medical records (stem cell source, use of TBI, conditioning 
chemotherapy used, other diagnoses, anti-infective and prophylactic and other 
medications used, the presence of acute and chronic GvHD, infectious complications, 
remission vs. recurrence of the disease, survival, and cause of death of non-survivors) 
were collected and examined. 
The control group consisted of 258 generally healthy Swiss volunteers (107 male and 
151 female, mean age of 43.5 years, age range 21-58 years) from the Swiss Bone 
Marrow Donor Registry. A thorough oral and periodontal examination of the control 
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9 DISCUSSION AND CONCLUSIONS 
9.1.1 Dental treatment needs in general 
The studies revealed that oral treatment needs were high and approximately 80% of 
patients had either caries or RAL > 3mm or both. This is in accordance with the findings 
of previous studies, which have shown that more than 90% of patients have some oral 
disease or need for dental treatment before HSCT [9, 45, 50]. Furthermore, in another 
study, approximately 50% of the 86 HSCT recipients had decayed teeth and needed oral 
hygiene instruction [51]. However, it is not possible to make a precise comparison 
between studies, as many parameters differ (e.g., the categories for oral disease and 
disorder, outcome variables, and the non-homogenous patient groups). The scarcity and 
heterogeneity of studies about common oral diseases among HSCT recipients has been 
noted in previous reviews, guidelines, and a report about caries and periodontitis in 
cancer survivors [63, 102, 143]. For example, the mean age of the participants in the 
different studies listed in Table 3 is notably varied (mean range 32-53 years). It is well-
known that oral health reduces with age, and the oral health of younger study 
participants was better than that of older adults.  
It can be assumed that previous cancer therapies may have weakened the oral health of 
some patients prior to HSCT, as, in the preceding years, they may have received 
different therapies (e.g., several chemotherapy cycles and medications). While the 
results of studies on the influence of chemotherapies on salivary flow rates in cancer 
patients are contradictory and limited, as stated in a recent review article [39], this thesis 
shows that patients with newly diagnosed haematological disease had worse values for 
oral health parameters when compared to controls, supporting the data from two other 
recent studies [42, 43]. Thus, previous cancer therapies cannot – at least not entirely – 
explain poor oral health before HSCT. 
 
9.1.2 Hyposalivation and its secondary consequences 
A novel finding of the second sub-study (8.2), with its remarkable number of patients, 
SSFR was observed to be lower in patients with newly diagnosed haematological 
malignancy or disease than in controls. Similar results have been observed in a small 
study of 24 patients conducted in the 1990s [44]. In the first sub-study (8.1), the mean 
SSFR was significantly lower in the patient group when compared to controls. In the 





longitudinal study (8.3) had SSFR ≤0.7ml/min. Likewise, the high prevalence of 
hyposalivation before HSCT was supported by a study of 228 allogeneic HSCT 
recipients [103]. Previous studies have observed that SSFR decreases after HSCT and 
returns back to pre-HSCT levels one year post-HSCT [102, 103]. 
No associations were observed with diagnosis, medications used, number of 
chemotherapies, or number of days from diagnosis with SSFR; and the reasons for the 
lower SSFR remain unclear and needs further investigation. The effect of chemotherapy 
to salivary flow rates has been assessed in previous studies but, as shown in a review 
article, the effect remains unclear and the results are contradictory [39]. The 
psychological effects of stress, anxiety, and depression are commonly experienced by 
HSCT recipients before and during the transplantation process [53]. These factors might 
have an influence on SSFR and should be considered a possible cause of salivary flow 
reduction. 
As some of the HSCT recipients suffer from reduced salivary flow rate even decades 
after HSCT [103], they should be provided with intensive preventive care and regular oral 
examinations. A study of patients with palliative cancer care showed that oral 
comorbidities were common, but the information about oral adverse effects of cancer 
therapies was insufficient and only 30% had received instructions and information on the 
importance of oral hygiene during and after therapies [141]. 
 
9.1.3 Caries and DMFT 
The WHO supports the diagnosis of caries lesions in epidemiological studies if the 
surface of teeth is softened or a cavity is present. Early stages of caries are thus not 
recommended for inclusion. 
The prevalence of cavitated lesions or lesions with soft surface in this thesis varied from 
33% to 44%, falling into the lower range of the findings from other studies (see Table 3). 
In addition, in the second sub-study (8.2), caries was more common among patients with 
newly diagnosed haematological disorder or malignancy and before HSCT than among 
the controls. Previous such comparisons of haematological adult patients and controls 
are very sparse. However, the results are supported by a study in which 39 newly 
diagnosed AL patients had significantly more caries and fewer teeth than the healthy 





In some studies (Table 3), the very high (up to 67% [47]) prevalence of caries or the 
difference between compiled caries and required fillings raises the question of whether 
early stage decays were also included. Occasionally, the studies separately categorised 
carious teeth and required fillings [45, 50, 51]. Indeed, fillings may be needed due to 
reasons other than caries, such as a chipped tooth or lost filling, which indicates previous 
caries or disorders other than active caries, such as erosion and trauma. However, the 
guidelines followed for clinical oral diagnoses in those studies were often not described. 
The reason for higher caries prevalence at the time of diagnosis warrants further study. 
The patients in this thesis received chemotherapy as part of HSCT. The prevalence of 
caries in cancer survivors was reported to be the highest for those who received 
chemotherapy, followed by those who underwent irradiation or a combination of the two 
[143]. The difference in caries prevalence could be due to the patient group receiving 
only radiation also consisting often of patients with head and neck cancer. The treatment 
protocols for eliminating possible oral foci before cancer treatment are more aggressive 
for patients with head and neck cancer, leading to higher DMFT due to missing teeth; but 
if oral foci elimination and intensive preventive approaches succeed, this leads to a 
decreased incidence of caries.  
Longitudinal studies about common oral diseases among HSCT recipients are very 
sparse and follow-up times have been short, comprising only months. In contrast, at the 
24-month follow-up in the third sub-study (8.3) of this thesis, it was observed that the 
DMFT index score was statistically significantly higher in HSCT recipients with 
hyposalivation than in those with normal SSFR. In the studies of this thesis, DMFT index 
was used to determine past and present cariological infections in HSCT recipients, and 
the incidences of new caries were also calculated. An earlier study of 36 HSCT 
recipients reported a statistically significant increase in DMFT index score at six months 
post-HSCT [46]. The third sub-study (8.3) did not confirm the previous findings, as no 
significant difference in DMFT index was found six months after HSCT. Likewise, two 
studies with a 100-day follow-up found no changes in DMFT index or increase in new 
dental caries lesions in this short time period [126, 144]. The findings of the third sub-
study (8.3) support the hypothesis that salivary measurements could be used as a 
potential predictive tool to detect oral comorbidities during and after HSCT. As 
hyposalivation was associated with increased DMFT index, it could be viewed as a risk 
factor for deterioration of oral health, eventually leading to tooth loss and expensive oral 
rehabilitation after HSCT. Additionally, although the observed caries prevalence was 





results were not statistically significant, except for HSCT recipients with hyposalivation 
pre-HSCT. However, the results may be underestimating the cariological problems in 
HSCT recipients post-HSCT, as all the patients were assigned to guidance and intensive 
prospective oral disease prevention programmes recommending use of extra fluoride 
and oral healthcare instructions during and after HSCT. Nevertheless, the oral health 
parameters worsened among HSCT recipients with hyposalivation, while these 
preventive measures are expected to prevent caries and reduce the effects of 
hyposalivation [63, 97, 140, 145]. 
 
9.1.4 Periodontitis 
According to WHO, almost 50% of adult population has at least some signs of 
periodontitis and almost all have signs of gingivitis [4]. The prevalence of periodontitis 
among both patients and controls in the studies of this thesis is in line with WHO data. 
Periodontal disease causing low-grade inflammation has been found to be associated 
with specific types of cancer (e.g., oral, oesophageal, and gastric) [6]. The survival of 
cancer patients with periodontitis was decreased [5]. Among patients with 
haematological cancer, the data on periodontitis prevalence are sparse, and consistent 
associations between increased risk of haematological malignancies and periodontitis 
have not been found [6]. Plaque accumulation causes periodontal inflammation such as 
bleeding and attachment loss in the normal population. It was hypothesised in a previous 
study of leukemic patients that poor periodontal parameters and bleeding could be 
correlated with haematological parameters, though no statistically significant results were 
found. As among the healthy population, an association was found between plaque 
accumulation and poor periodontal parameters [146]. In one cohort study (n = 48 375), a 
significant increase in bone loss was found (measured by radiographs) in non-Hodgkin’s 
lymphoma patients, but other types of haematological cancer had no significant 
association with bone loss [147]. Furthermore, the same group later updated the study 
and found periodontal disease to be a risk factor for non-Hodgkin’s lymphomas [7]. In 
this thesis, there was no statistically significant variance in prevalence of periodontitis 
(RAL > 3mm) for different haematological diagnoses, and a higher periodontitis 
prevalence was not found among patients with non-Hodgkin’s lymphoma when 
compared to controls or other haematological malignancies. Thus, this thesis does not 
support previous findings based on similar diagnostics methods. However, this could be 
due to the smaller patient population in this study. Moreover, periodontal diagnosis in this 





periodontal disease and do not provide as accurate data as when combined with clinical 
diagnostics. However, both cancers and periodontitis have many common and different 
confounding factors, which make analysis of the associations challenging.  
Several studies have investigated the association of periodontal health before HSCT with 
mucositis [8-10]. Professional dental care and instructions for intensive oral hygiene 
were associated with shorter and less severe grade of mucositis [10, 27, 94-96]. 
Mucositis can be life threatening, lengthen hospital stays, and cause discomfort for the 
patient. As the prevalence of periodontal problems is high, as shown in the studies of this 
thesis and elsewhere, recommendations should be followed for early oral examination 
and necessary periodontal interventions. Furthermore, positive outcomes for periodontal 
health after HSCT due to intensive preventive approaches and guidance for patients 
have been reported [9, 94]. 
It should be noted that the results of some previous studies may be unreliable. The very 
low prevalence of periodontitis (0.6% and 16% [48, 110]) is far from that in the general 
adult population, according to WHO [4]. Thus, the study showing an association between 
periodontitis and infection complications during HSCT must be treated with caution, 
despite its sample size being large [48]. In the third sub-study (8.3) of this thesis, an 
association was not seen between periodontitis prevalence and survival at six months, 
and there was no difference in periodontitis prevalence between patient and normal 
populations. 
 
9.1.5 Oral GvHD 
In the third longitudinal study (8.3), hyposalivation was not associated with acute or 
chronic GvHD or oral manifestation of GvHD. However, cGvHD has been found to affect 
salivary glands and lead to salivary dysfunction after the onset of GvHD [101, 148, 149]. 
Thus, it has been hypothesised that salivary gland involvement could be a separate 
manifestation of GvHD with or without oral mucosal signs, despite their anatomical 
proximity [122, 125]. In future studies, oral mucosal and salivary gland GvHD 
involvement should be investigated independently to clarify this issue. As the prevalence 
of hyposalivation was high before HSCT and the cytotoxic effects of chemotherapy and 
irradiation causing damage of salivary glands, involvement of GvHD is certainly not the 
only reason for reduced salivary flow rates. However, in this study, the SSFR of HSCT 





is in line with findings of previous studies, where malfunctions of salivary glands were 
reported in patients with cGvHD [101, 148, 150]. 
 
9.1.6 Oral health and survival 
The age- and sex-adjusted hazard ratio (HR) of dying within six months post-HSCT was 
almost twice as high in the hyposalivation group when compared to the group consisting 
of HSCT recipients without hyposalivation pre-HSCT. Previous studies have found 
associations between hyposalivation, frailty, and mortality. However, these studies were 
performed among older people with different medical backgrounds [151-153]. It could be 
assumed that patients with longer history of cancer treatment have decreased SSFR. 
However, surprisingly, the SSFR was also significantly lower among patients with newly 
diagnosed haematological disorders or malignancy. The use of SSFR as a predictor of 
survival needs further research.  
Caries was more common pre-HSCT in deceased patients than among recipients who 
survived more than six months (p < 0.05). High caries prevalence is related to low socio-
economic status and there is some evidence that low socio-economic status could have 
a negative impact on HSCT outcomes [4, 154]. Caries is also associated with poor life-
style habits, which could indicate poor overall health behaviours and delayed seeking of 
treatment for symptoms of the haematological malignancy and disorder. This could lead 
to delayed diagnosis and disease progression, thus worsening the prognosis. High 
caries prevalence could also be associated with poor oral health habits. Lack of regular 
tooth and oral cleaning could cause a shift to a more pathogenetic oral environment. 
Previous studies have found that good oral hygiene reduces the severity of mucositis 
and shortens its length. In the case of inadequate oral hygiene, these patients might 
have increased risk of mucositis, which can be lethal itself, and ulcerations caused by it 
can act as ports of infection [10, 47, 94]. The information about the socio-behavioural 
status and oral health habits of the patients in the studies of this thesis was not available, 
which could have verified this issue. Therefore, the reason for the lower survival rate 
among patients with higher caries prevalence could not be clarified.  
A recent cohort study found associations between periodontitis and overall cancer 
mortality [5]. In the third sub-study (8.3), periodontitis was somewhat higher pre-HSCT in 
patients who were deceased within six months after HSCT than among survivors, though 
the difference did not reach statistical significance. The method used in this thesis to 





inaccurate and could lead to underestimation of the effect of periodontitis on post-HSCT 
comorbidity and survival. Thus, these results must be observed with caution.  
 
9.1.7 Acute oral infections 
Studies in the 1980s and 1990s found that infections of oral origin were common during 
HSCT [60, 66, 68, 69]. However, oral health has significantly improved in Western 
Europe and the oral health of the average HSCT patient can be assumed to have 
improved since the 1980s [4]. Even more important for the increased success of HSCT 
are the improvements achieved in HSCT procedures in recent decades, leading to 
increased survival rates [23]. In the first and second sub-studies (8.1 and 8.2), 
symptomatic acute oral infections were found among 5.4-6.3% patients pre-HSCT and in 
none of the controls. The results are in the same range of those of a study among 
autologous HSCT recipients and patients who received high-dose chemotherapy, as 
6.4% had acute infections before therapy began [49]. This supports the guidelines for 
early as possible oral examination to treat and eliminate these obvious infection foci 
before HSCT.  
In a prospective study of 86 patients with haematological malignancy, it was found that 
patients with incomplete dental interventions had statistically significantly more frequent 
inflammatory complications during chemotherapy. A positive oral origin blood culture was 
found in one patient, but without any oral signs. In no cases was chemotherapy 
interrupted or postponed due to odontogenic infection [65]. It must be noted that the 
patients, who still had possibly untreated oral foci could not be treated because 
chemotherapy took priority, due to the stage of the haematological cancer, which might 
itself cause higher risk for complications. However, in contrast, another recent study 
found no difference in risk of bacteraemia during and after HSCT among patients with 
compromised dental status and among those whose dental treatment needs were met 
[71]. Additionally, non-symptomatic chronic oral infections could be left untreated, as 
they probably do not cause infections during HSCT [49, 77]. There are many reasons 
why the spread of oral infections to systemic infection is today significantly less common 
than in the 1980s; for example, oral health in general has improved in recent decades, 
and patients are provided with prophylactic anti-microbial medications. Infections as a 
cause of death among HSCT recipients have significantly decreased [23]. In the third 
sub-study (8.3), the reason for death was in most cases marked as HSCT-related or due 





compiled, and similar results were found in a recent study where oral infections were not 
associated with infectious complications [77]. 
 
9.2 Clinical relevance of the studies and summary 
The results of this thesis could be used to assess the oral health of HSCT recipients. The 
importance of improving treatment protocols to offer good, supportive care to patients 
with severe haematological malignancies and disorders has been shown. The high 
prevalence of common oral diseases and disorders before and after HSCT among these 
patients has been observed, which supports the guidelines for oral care interventions 
among patients before and after HSCT.  
The oral health of patients with a newly diagnosed haematological malignancy and 
disease and patients with upcoming HSCT was investigated, and their respective dental 
treatment needs were found to be substantial. Caries, acute infections, and DMFT index 
were high, when compared with control groups. The longitudinal changes of oral health 
parameters were also assessed and patients with hyposalivation can be considered at 
an elevated risk of further oral health problems (higher caries prevalence, elevated 
DMFT index, and reduced number of teeth). Hyposalivation and caries were also 
associated with lower survival rate. 
Based on these results, it is recommended that oral health be examined at the time of 
diagnosis, as the patients are strongly in need of oral and dental treatment. 
The novel findings for reduced salivary flow rates in patients before HSCT, compared to 
the controls, and their possible association with survival will raise new questions for 
future research. The importance of saliva should not be underestimated and patients 
with reduced SSFR should be informed of the necessary preventive approaches to 
maintain oral function before HSCT. The use of SSFR measurement as a cost-effective 
and easy predictor of higher risk of oral comorbidity is recommended. 
9.3 Limitations 
The heterogeneity of the study population can be considered as a limitation of this study. 
The diagnoses varied, and ALL was the most common, though several others were 





third sub-study (8.3), patients’ oral health parameters were compared according to their 
diagnoses and no statistically significant differences were found. It may be that more 
precise results could be achieved by working with larger patient groups, with analyses 
conducted separately for each diagnosis. 
In the longitudinal study, there was a notable loss of patients. Mortality explains only a 
part of this loss, as 101 HSCT recipients died during the 24-month study period. The 
greater involvement of the patients in the follow-up and larger study groups could 
strengthen this analysis, as mentioned above. Additionally, as the longitudinal data 
collection was retrospective, when missing follow-up was noted, patients could not be 
called in for examinations as the relevant timepoints had passed. 
Moreover, the information about the patients’ socio-behavioural status, oral hygiene 
habits, and regularity of dentist visits before the first intervention in the UZB OHM clinic 
was unknown. 
In general, the patients should have been sent to the oral examination; but the 
examinations could not be done if the general health status of the patient did not allow 
her to be transported to the dental clinic. This might have excluded some of those with 
worse general health conditions at the time of diagnosis or pre-HSCT. This is, however, 
a minor proportion of the patients and probably did not cause bias to the results. 
The patients were often neutropenic and anaemic; thus, the diagnosis of present or 
previous periodontitis was based on radiographs and RAL. This method can lead to 
inaccuracies in the diagnosis of periodontitis, preventing determination of the activity of 
the disease. Early signs of periodontal disease and gingivitis cannot be recorded using 
this method. This limitation could be considered a weakness of the methodology. 
 
9.4 Implications for future research 
It remains unclear why worse oral health was observed among patients with newly 
diagnosed severe haematological disorder or malignancy, compared with controls, and 
further studies are thus needed. The socio-behavioural aspect and history of dental 






Further longitudinal studies are needed to gather evidence-based data on tooth 
sensitivity. This is commonly mentioned in the guidelines, but as yet, no studies have 
sought evidence from HSCT patients.  
The use of saliva as a predictor of survival warrants further investigation. Medications, 
age, or other analysed factors do not reveal the reason for lower SSFR in the deceased 
patients, and additional investigations are needed to clarify the issue. The impact of 
periodontal disease or gingivitis on survival should be studied using a more accurate 
diagnostic method. The role of acute and chronic oral infections in patient death should 
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